title: Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis             via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
abstract: Angiogenesis is crucial for cancer growth and metastasis and inhibition             of angiogenesis has been recognized to be a promising strategy for the treatment             of cancer. Traditional Chinese medicine (TCM) has been used for thousands of years             to treat cancer. Jiedu Xiaozheng Yin (JXY), a polyherbal formula of TCM, has been             used to treat various tumors in China. However, the mechanism of its anticancer             activity has yet to be fully elucidated. Using human umbilical vein endothelial             cells (HUVECs), chick chorioallantoic membrane (CAM) and a hepatoma mouse xenograft             model, we investigated the underlying molecular mechanisms of ethanol extract             of Jiedu Xiaozheng Yin (EE-JXY). EE-JXY treatment significantly inhibited tumor             cell growth both in vitro and in the mouse xenograft model (P<0.05). Moreover,             EE-JXY reduced tube formation of HUVECs and angiogenesis in the CAM (P<0.01)             and microvessel density (MVD) of tumor in vivo (P<0.05). Further studies showed             that EE-JXY was able to suppress the expression of vascular endothelial growth             factor A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR-2)             in both HepG2 cells and HUVECs (P<0.01) and in tumor (P<0.01). Thus, JXY             suppressed tumor growth at least by inhibiting angiogenesis.
authors.affiliation: Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, PR China.
authors.forename: Zhiyun
authors.initials: Z
authors.lastname: Cao
authors.forename: Wei
authors.initials: W
authors.lastname: Lin
authors.forename: Zhengrong
authors.initials: Z
authors.lastname: Huang
authors.forename: Xuzheng
authors.initials: X
authors.lastname: Chen
authors.forename: Jinyan
authors.initials: J
authors.lastname: Zhao
authors.forename: Liangpu
authors.initials: L
authors.lastname: Zheng
authors.forename: Hongzhi
authors.initials: H
authors.lastname: Ye
authors.forename: Zhizhen
authors.initials: Z
authors.lastname: Liu
authors.forename: Lianming
authors.initials: L
authors.lastname: Liao
authors.forename: Jian
authors.initials: J
authors.lastname: Du
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002642:Chick Embryo; D049033:Chorioallantoic Membrane / Q000098:blood supply / Q000187:drug effects; D015536:Down-Regulation; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects*; D056945:Hep G2 Cells; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D055806:Microvessels / Q000187:drug effects / Q000473:pathology; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D047368:Tumor Burden / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D004365:Drugs, Chinese Herbal; C587679:Jiedu Xiaozheng Yin; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D040301:Vascular Endothelial Growth Factor Receptor-2